In 2020, 1.5 million new HIV cases were reported worldwide. To end the HIV epidemic, effective prevention strategies are critical. The efficacy and effectiveness of the first approved PrEP regimens at the individual and population levels have fueled further research, and we are currently in the midst of a new exciting chapter. The diversity in new drugs and their formulations, including long-acting injectables, implants, and vaginal rings highlights a sustained educational need. Real-world data suggest different challenges in PrEP implementation, such as the perception of risk, compromised adherence, costs, availability, and structural barriers. Implementation challenges reflect regional differences in healthcare settings indicating a need for tailored educational programs to discuss best practices and better align guidelines and policies inclusive to all at-risk groups.
The HIV Prevention Series is designed to promote understanding among physicians, nurses, policymakers, and community advocates on antiretroviral drugs for prevention, novel formulations, and devices. It also includes implementation strategies and individual and community-based behavioral aspects of prevention as well as insights into the vaccine landscape and prospects of monoclonal antibodies for HIV prevention.
The Asia-Pacific HIV Prevention Meeting 2022 focused on regional guidelines, barriers to PrEP access, and strategies to overcome them. The program was designed in collaboration with eminent regional experts and reflect on region-specific healthcare settings and access to drugs and services.
